Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
出版年份 2022 全文链接
标题
Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
作者
关键词
-
出版物
Frontiers in Oncology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-01-06
DOI
10.3389/fonc.2021.783309
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of 6,8-Diprenylgenistein on VEGF-A-Induced Lymphangiogenesis and Lymph Node Metastasis in an Oral Cancer Sentinel Lymph Node Animal Model
- (2021) Mun Gyeong Bae et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lymphatic Vasculature: An Emerging Therapeutic Target and Drug Delivery Route
- (2021) Wenjing Xu et al. Annual Review of Medicine
- Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway
- (2021) Bin Huang et al. BIOMEDICINE & PHARMACOTHERAPY
- MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3
- (2021) Aya Yamamura et al. Frontiers in Pharmacology
- FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
- (2021) Luckson N. Mathieu et al. CLINICAL CANCER RESEARCH
- Regulation of VEGFR Signalling in Lymphatic Vascular Development and Disease: An Update
- (2021) Genevieve A. Secker et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients
- (2021) Philippe Aftimos et al. Biomedicines
- Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
- (2021) Jinchun Wu et al. Frontiers in Oncology
- Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
- (2020) Sung-Hwa Sohn et al. OncoTargets and Therapy
- Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification
- (2020) Bum Jun Kim et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
- (2020) Mojun Zhu et al. INVESTIGATIONAL NEW DRUGS
- The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease
- (2020) Guillermo Oliver et al. CELL
- Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer
- (2019) Jia Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice
- (2019) Seun Deuk Hwang et al. Cell Death & Disease
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and Anti-Tumor Activity
- (2019) Hui K Gan et al. CLINICAL CANCER RESEARCH
- Phomaketide A Inhibits Lymphangiogenesis in Human Lymphatic Endothelial Cells
- (2019) Huai-Ching Tai et al. Marine Drugs
- Innovative therapies for neovascular age-related macular degeneration
- (2019) Hasenin Al-Khersan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
- (2019) Ignace Vergote et al. LANCET ONCOLOGY
- Hedyotis diffusa Willd. inhibits VEGF‑C‑mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways
- (2019) Huang Li et al. ONCOLOGY REPORTS
- Identification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis
- (2019) Youngsun Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- 3‐ O ‐Acetyloleanolic acid inhibits angiopoietin‐1‐induced angiogenesis and lymphangiogenesis via suppression of angiopoietin‐1/Tie‐2 signaling
- (2019) Jeon Hwang‐Bo et al. PHYTOTHERAPY RESEARCH
- Key molecules in lymphatic development, function, and identification
- (2018) Sawan Kumar Jha et al. ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER
- 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model
- (2018) Jeon Hwang-Bo et al. BMC CANCER
- Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
- (2018) David M. Hyman et al. CLINICAL CANCER RESEARCH
- First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
- (2018) Vicki L. Keedy et al. INVESTIGATIONAL NEW DRUGS
- Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
- (2018) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis
- (2018) Yuanqi Liu et al. Journal of Natural Medicines
- Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review
- (2018) Michael Yamakawa et al. MEDICINAL RESEARCH REVIEWS
- Aspirin suppresses components of lymphangiogenesis and lymphatic vessel remodeling by inhibiting the NF-κB/VCAM-1 pathway in human lymphatic endothelial cells
- (2018) Orawin Prangsaengtong et al. VASCULAR MEDICINE
- A comprehensive review of protein kinase inhibitors for cancer therapy
- (2018) Radhamani Kannaiyan et al. Expert Review of Anticancer Therapy
- Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition
- (2018) Orawin Prangsaengtong et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients With Advanced Solid Tumors
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
- (2018) John H. Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Advanced and Refractory Desmoid Tumors
- (2018) Mrinal M. Gounder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation
- (2017) Caiqi Ma et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
- (2017) Melissa García-Caballero et al. Journal of Hematology & Oncology
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Cervical cancer cell–derived angiopoietins promote tumor progression
- (2017) Ping Yang et al. TUMOR BIOLOGY
- Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
- (2017) Tong Lin et al. Drug Design Development and Therapy
- The Natural Antiangiogenic Compound AD0157 Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells
- (2017) Melissa García-Caballero et al. Frontiers in Pharmacology
- First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor.
- (2017) D. S. Mendelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor lymphangiogenesis and new drug development
- (2016) Lothar C. Dieterich et al. ADVANCED DRUG DELIVERY REVIEWS
- Lymphangiogenesis in rat asthma model
- (2016) Aigul Moldobaeva et al. ANGIOGENESIS
- Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels
- (2016) Ji Yoon Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways
- (2016) Igor Hrgovic et al. BMC CANCER
- Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway
- (2016) M García-Caballero et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
- (2016) Muhammad Wasif Saif et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
- (2016) Hidehiko Takigawa et al. CANCER SCIENCE
- A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors
- (2016) A. Dowlati et al. CLINICAL CANCER RESEARCH
- Dimethylfumarate effectively inhibits lymphangiogenesis via p21 induction and G1 cell cycle arrest
- (2016) Eva Maria Valesky et al. EXPERIMENTAL DERMATOLOGY
- Novel anti-angiogenic therapeutic strategies in colorectal cancer
- (2016) M. Tampellini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of fatty acid β-oxidation in lymphangiogenesis
- (2016) Brian W. Wong et al. NATURE
- Fucoidan inhibits lymphangiogenesis by downregulating the expression of VEGFR3 and PROX1 in human lymphatic endothelial cells
- (2016) Yazong Yang et al. Oncotarget
- Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling
- (2016) Yu-Wen Yeh et al. Oncotarget
- The Antitumor Effect of Gekko Sulfated Glycopeptide by Inhibiting bFGF-Induced Lymphangiogenesis
- (2016) Xiu-Li Ding et al. Biomed Research International
- Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells
- (2015) Jaeyoung Lim et al. CANCER INVESTIGATION
- Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
- (2015) A. Hultberg et al. CANCER RESEARCH
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2015) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
- (2015) David S. Hong et al. Oncotarget
- Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab
- (2015) Dhruv Kumar et al. JAMA Otolaryngology-Head & Neck Surgery
- Lymphangiogenic factors, mechanisms, and applications
- (2014) Wei Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
- (2013) F. Bladt et al. CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation
- (2013) V.-M. Leppanen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases
- (2013) Felix Bock et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model
- (2012) Xiping Xin et al. LABORATORY INVESTIGATION
- Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor
- (2012) H. Y. Zou et al. MOLECULAR CANCER THERAPEUTICS
- Mechanoinduction of lymph vessel expansion
- (2011) Lara Planas-Paz et al. EMBO JOURNAL
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- (2011) M.J.A. de Jonge et al. EUROPEAN JOURNAL OF CANCER
- Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
- (2010) I R H M Konings et al. BRITISH JOURNAL OF CANCER
- Suppression of Tumor Growth and Metastasis by Simultaneously Blocking Vascular Endothelial Growth Factor (VEGF)-A and VEGF-C with a Receptor-Immunoglobulin Fusion Protein
- (2010) D. Zhang et al. CANCER RESEARCH
- Neuropilin-2 mediates VEGF-C–induced lymphatic sprouting together with VEGFR3
- (2010) Yunling Xu et al. JOURNAL OF CELL BIOLOGY
- Phage-Derived Fully Human Monoclonal Antibody Fragments to Human Vascular Endothelial Growth Factor-C Block Its Interaction with VEGF Receptor-2 and 3
- (2010) Matthias Rinderknecht et al. PLoS One
- Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model
- (2009) M Yashiro et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search